Optimal dosing and duration of linezolid for the treatment of multidrug-resistant and rifampicin-resistant tuberculosis: an individual patient data meta-analysis.

Eur Respir J · 2025 · PMC12371315 · PMID 40675768

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Compared with group 2, group 1 had a higher rate of adverse events (adjusted SHR 1.84, 95% CI 0.75–4.50), while group 3 showed a lower rate (adjusted SHR 0.55, 95% CI 0.18–1.67), although these differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.